Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Alessandro M. Gianni et al.|Journal of Clinical Oncology|2010Cited by 167
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi SurveyCorrado Tarella, Alessandro Rambaldi, Manuela Zanni et al.|Journal of Clinical Oncology|2008Cited by 72
Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter StudyMarco Ruella, Liliana Devizzi, Andrea Riccardo Filippi et al.|International Journal of Radiation Oncology*Biology*Physics|2015Cited by 48
Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAMLiliana Devizzi, Alessandro M. Gianni, Anna Guidetti et al.|Journal of Clinical Oncology|2013Cited by 14
Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients.Corrado Tarella, Alessandro Rambaldi, Manuela Zanni et al.|Blood|2006Cited by 4